BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35177256)

  • 1. [When to consider type I interferonopathy in adulthood?].
    David C; Frémond ML
    Rev Med Interne; 2022 Jun; 43(6):347-355. PubMed ID: 35177256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Type I interferonopathies. Literature review].
    Picard C; Belot A
    Rev Med Interne; 2018 Apr; 39(4):271-278. PubMed ID: 27659742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic interferonopathies: An overview.
    Eleftheriou D; Brogan PA
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
    Yu ZX; Song HM
    World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome.
    Kong XF; Worley L; Rinchai D; Bondet V; Jithesh PV; Goulet M; Nonnotte E; Rebillat AS; Conte M; Mircher C; Gürtler N; Liu L; Migaud M; Elanbari M; Habib T; Ma CS; Bustamante J; Abel L; Ravel A; Lyonnet S; Munnich A; Duffy D; Chaussabel D; Casanova JL; Tangye SG; Boisson-Dupuis S; Puel A
    J Clin Immunol; 2020 Aug; 40(6):807-819. PubMed ID: 32572726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.
    de Jesus AA; Hou Y; Brooks S; Malle L; Biancotto A; Huang Y; Calvo KR; Marrero B; Moir S; Oler AJ; Deng Z; Montealegre Sanchez GA; Ahmed A; Allenspach E; Arabshahi B; Behrens E; Benseler S; Bezrodnik L; Bout-Tabaku S; Brescia AC; Brown D; Burnham JM; Caldirola MS; Carrasco R; Chan AY; Cimaz R; Dancey P; Dare J; DeGuzman M; Dimitriades V; Ferguson I; Ferguson P; Finn L; Gattorno M; Grom AA; Hanson EP; Hashkes PJ; Hedrich CM; Herzog R; Horneff G; Jerath R; Kessler E; Kim H; Kingsbury DJ; Laxer RM; Lee PY; Lee-Kirsch MA; Lewandowski L; Li S; Lilleby V; Mammadova V; Moorthy LN; Nasrullayeva G; O'Neil KM; Onel K; Ozen S; Pan N; Pillet P; Piotto DG; Punaro MG; Reiff A; Reinhardt A; Rider LG; Rivas-Chacon R; Ronis T; Rösen-Wolff A; Roth J; Ruth NM; Rygg M; Schmeling H; Schulert G; Scott C; Seminario G; Shulman A; Sivaraman V; Son MB; Stepanovskiy Y; Stringer E; Taber S; Terreri MT; Tifft C; Torgerson T; Tosi L; Van Royen-Kerkhof A; Wampler Muskardin T; Canna SW; Goldbach-Mansky R
    J Clin Invest; 2020 Apr; 130(4):1669-1682. PubMed ID: 31874111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Type I interferonopathies].
    Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
    Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung involvement in monogenic interferonopathies.
    Cazzato S; Omenetti A; Ravaglia C; Poletti V
    Eur Respir Rev; 2020 Dec; 29(158):. PubMed ID: 33328278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I Interferonopathies in Childhood.
    Haşlak F; Kılıç Könte E; Aslan E; Şahin S; Kasapçopur Ö
    Balkan Med J; 2023 May; 40(3):165-174. PubMed ID: 37161741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of type I interferon signatures in undifferentiated inflammatory diseases: A Japanese multicenter experience.
    Miyamoto T; Honda Y; Izawa K; Kanazawa N; Kadowaki S; Ohnishi H; Fujimoto M; Kambe N; Kase N; Shiba T; Nakagishi Y; Akizuki S; Murakami K; Bamba M; Nishida Y; Inui A; Fujisawa T; Nishida D; Iwata N; Otsubo Y; Ishimori S; Nishikori M; Tanizawa K; Nakamura T; Ueda T; Ohwada Y; Tsuyusaki Y; Shimizu M; Ebato T; Iwao K; Kubo A; Kawai T; Matsubayashi T; Miyazaki T; Kanayama T; Nishitani-Isa M; Nihira H; Abe J; Tanaka T; Hiejima E; Okada S; Ohara O; Saito MK; Takita J; Nishikomori R; Yasumi T
    Front Immunol; 2022; 13():905960. PubMed ID: 36211342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.
    Melki I; Frémond ML
    Curr Rheumatol Rep; 2020 Jun; 22(7):32. PubMed ID: 32548765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].
    Günther C; Schmidt F; König N; Lee-Kirsch MA
    Z Rheumatol; 2016 Mar; 75(2):134-40. PubMed ID: 26744186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome.
    Meuwissen ME; Schot R; Buta S; Oudesluijs G; Tinschert S; Speer SD; Li Z; van Unen L; Heijsman D; Goldmann T; Lequin MH; Kros JM; Stam W; Hermann M; Willemsen R; Brouwer RW; Van IJcken WF; Martin-Fernandez M; de Coo I; Dudink J; de Vries FA; Bertoli Avella A; Prinz M; Crow YJ; Verheijen FW; Pellegrini S; Bogunovic D; Mancini GM
    J Exp Med; 2016 Jun; 213(7):1163-74. PubMed ID: 27325888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy.
    Chia J; Eroglu FK; Özen S; Orhan D; Montealegre-Sanchez G; de Jesus AA; Goldbach-Mansky R; Cowen EW
    J Am Acad Dermatol; 2016 Jan; 74(1):186-9. PubMed ID: 26584874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Musculoskeletal Disease in MDA5-Related Type I Interferonopathy: A Mendelian Mimic of Jaccoud's Arthropathy.
    de Carvalho LM; Ngoumou G; Park JW; Ehmke N; Deigendesch N; Kitabayashi N; Melki I; Souza FFL; Tzschach A; Nogueira-Barbosa MH; Ferriani V; Louzada-Junior P; Marques W; Lourenço CM; Horn D; Kallinich T; Stenzel W; Hur S; Rice GI; Crow YJ
    Arthritis Rheumatol; 2017 Oct; 69(10):2081-2091. PubMed ID: 28605144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
    Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
    Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monogenetic causes of chilblains, panniculitis and vasculopathy: the Type I interferonopathies.
    Papa R; Volpi S; Gattorno M
    G Ital Dermatol Venereol; 2020 Oct; 155(5):590-598. PubMed ID: 32618445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies.
    Pescarmona R; Belot A; Villard M; Besson L; Lopez J; Mosnier I; Mathieu AL; Lombard C; Garnier L; Frachette C; Walzer T; Viel S
    Cytokine; 2019 Jan; 113():446-452. PubMed ID: 30413290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COPA syndrome, 5 years after: Where are we?
    Frémond ML; Nathan N
    Joint Bone Spine; 2021 Mar; 88(2):105070. PubMed ID: 32919065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
    Kim H; Sanchez GA; Goldbach-Mansky R
    J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.